Archive | Hot Mandates RSS feed for this section

Hot Life Science Investor Mandate 3: Venture Capital Fund Seeking Early Stage Diagnostics and 510k Devices

24 Jul

A venture capital firm based in the Mid-Western United States is looking to make equity investments into early stage companies ranging from $250,000 – $2.5 million. The firm is actively reviewing opportunities throughout the United States with a preference for companies located in the Mid-West.

The firm is looking for companies in sectors of Medical Devices, Diagnostics and Healthcare IT. In the device space, the firm is looking for companies with 510k regulatory pathways and is not interested in companies requiring PMA’s or therapeutic companies. The firm is open to all technologies types and indications within those areas. The firm looks to get involved in early stages of company formation. The firm’s current portfolio includes life science companies working with Genomic testing and in-vivo robotic surgical devices.

The firm is looking for privately held companies with experienced management teams. The firm looks to take a board seat following investment and is open to working with companies in filling and building out management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Life Science Investor Mandate 1: Family Office Seeking Life Science Investments Globally

17 Jul

A family office founded by a successful medical device entrepreneur can make investments ranging from approximately $500,000 to $100 million into companies and due to its funding structure has no requirements for holding period or capital structure. The firm makes investments in the forms of equity, controlling interest, in-licensing, MBO/LBO, growth capital and is also willing to co-invest. The firm is looking for companies located around the globe and makes around 5-15 investments in a given year.

The firm is looking for companies in sectors of Biotech Therapeutics and Diagnostics, Medtech, Heathcare IT, R&D Services, and Biotech Other. The firm is willing to consider all indications including orphan diseases, though they have some additional interest/experience in areas of Women’s Health, GI, Oncology, Cardiovascular, and Personalized Medicine including Proteomics and Genomics. The firm is most interested in companies that are in Phase II or later, nearing commercialization where the firm is capable of utilizing its operating company to scale up the company’s sales, marketing and distribution. That being said the firm has made earlier stage investments in the past and is open to considering highly innovative and compelling early stage companies. The firm is also interested in companies developing consumables/reagents, service providers, food and nutraceuticals.

The firm looks to work with management teams with experience and grit and generally looks to take a board seat although it is not a requirement. The firm looks to leverage the use of its operating company to assist the company’s sales marketing and distribution efforts as well as providing assistance in operations management.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Tags: , , , , , ,

Hot Life Science Investor Mandate 2: CVC of Large Pharma Looking Opportunistically for Life Science Investments

17 Jul

The Corporate Venture Capital arm of a Global Pharmaceutical company provides seed and venture capital to development stage companies within life science and biotechnology. The firm provides pre-seed grants and seed investments to early-stage life science projects in Scandinavia. The firm’s venture investment activities are structured as an open evergreen fund. The firm invests at any stage of development – seed, venture, and growth. The firm also makes late-stage investments in public/private companies with a positive cash flow. The firm can allocate up to $30M per company, but generally allocates between $5M to $20M. The firm seeks companies that are based in North America and Europe. The firm has no current mandate for the number of allocations it plans to make and will evaluate relevant opportunities as they surface.

The firm is opportunistic in the life sciences space. The firm specifically focuses on companies that specialize in the development of novel drugs, new procedures for diagnosis and control of diseases, development of medical devices and instruments, and industrial biotechnology.  The firm is open to all technology and indication areas within these sectors. 

The firm seeks company ownership in return for its seed investments and influential equity ownership for late-stage investments. The firm considers both pre-revenue and revenue generating private and public companies.  The firm is generally opportunistic with the management team, but highly prefers an experienced and qualified management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Tags: , , , ,

Hot Life Science Investor Mandate 3: Global VC Firm Seeking Investments for Multiple Funds

17 Jul

A Venture Capital firm, with offices in the Eastern US and Europe, currently manages three active funds, two focused on private equities and one focused on public equities. The firm is currently in the process of raising a private equity fund that it plans to have its first close in Sept/Oct 2014. The firm’s private equity funds make investments in the form of preferred equity; the public equity fund invests in the form of PIPEs and public market placements. The size of the firm’s investments is highly varied, as the firm pursues a great variety of opportunities with investments falling anywhere in the €2-€15 million range. The firm is actively seeking new investments in the life science sector, and will consider potential opportunities in Europe and North America.

The firm’s new fund plans to invest broadly in the life sciences across sectors of therapeutics, diagnostics, devices and healthcare IT. The fund is very open across stage, indication and technology types with a slight preference for companies working with platform technologies. The firm also manages a fund that focuses on medical devices, diagnostics and healthcare IT companies with products on the market or close to commercialization. With this fund the firm specifically looks for opportunities that are both increasing quality and reducing the cost of care.

The firm places a considerable focus on technology when vetting deals; the partners of the firm are MDs, PhDs or both. In addition to strong technology the firm prefers to invest in management teams with strong track records and deep domain expertise, preferably with prior experience of achieving success in a venture-backed life science company. The firm generally looks to take a board seat following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Tags: , , , , , ,

Hot Life Science Investor Mandate 1: Single Family Office Seeking Global Opportunities in Brain Health

10 Jul

A Single Family Office based in the western United States makes seed-stage and venture-stage equity investments; typical seed investments are of $250,000-500,000 initially with the potential for follow-on financing of up to $3 million.  The firm is open to opportunities worldwide, and currently has portfolio companies in North America, Europe and Oceania.

The firm focuses on brain health, with 80% of the fund’s investments occurring in this indication area.  The firm’s mandate encompasses both diseases of the nervous system and psychiatric disorders, with a particular interest in Alzheimer’s disease.  The firm is open to investing in therapeutics, diagnostics and medical devices, and is interested in interdisciplinary approaches.  The firm seeks early-stage opportunities, but will also consider later-stage opportunities.  The firm’s prior investments include drug discovery for treatments for Alzheimer’s disease, and novel diagnostics including a tool that tracks early cognitive decline.

The firm strongly prefers to invest in privately held companies.  The firm only backs top scientists pursuing breakthrough approaches, and does not invest in “me-too” ideas.  In the medical technology sector the firm prefers to invest in companies developing platform technologies with multiple potential applications.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Tags: , , , ,

Hot Life Science Investor Mandate 2: Health Insurance Provider Seeking Shipping Medical Devices/Diagnostics

10 Jul

A US based Health Insurance Provider makes investments in healthcare companies from an evergreen investment fund.  Allocation sizes are highly varied, but are most often $3-5 million.  While the firm is open to opportunities globally, the organization only invests in companies that are targeting the US healthcare market (including companies with products that have been commercialized in other markets and are seeking capital to expand into the US market).

The firm invests in transformative medical technologies that will lower the cost of care provision, and has previously made investments in healthcare IT and in wearable sensors for elderly patients.  The firm only invests in companies that have attained regulatory approval for their products, or which do not require approval.  The fund does not invest in therapeutics, but is open to investing in diagnostic technologies that will lower the cost of care.  In the medical device sector, the firm is generally not interested in invasive devices such as implantable.

While the firm is open to investing in any indication area, the firm’s focus is on population health and the firm is therefore primarily interested in indications with a large number of patients, including cancer, diseases of the nervous system, and diabetes.

The firm invests in both pre-revenue companies and companies with existing revenues, but does not invest in companies that still face regulatory barriers to attaining revenue.  The firm has long-term horizons for investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Tags: , , ,

Hot Life Science Investor Mandate 3: VC Fund Looking Opportunistically in the Life Sciences

10 Jul

A Venture Capital company with offices in the Eastern and Western United States is looking to make equity investments ranging from approximately $3-$5 million initially and $10-$25 million over the investment’s lifetime. The firm looks for companies primarily in the United States, and some select opportunities in Europe. The firm plans to make between 1-5 investments over the next year.

The firm is interested in sectors of Biotech Therapeutics, Diagnostics, Medical Devices, Life Science Tools and Healthcare IT. In the Therapeutics space the firm is looking for both small molecule and biologics that are 1 year from entering clinical trials or later with a preference for companies that have in human data. The firm is generally open to all indications but is especially interested in areas of Oncology, Immunology and Orphan Diseases. For Medical Devices, Diagnostics and Life Science Tools the firm prefers to make later stage investments into companies that have significant in human data or have already been commercialized.

The firm is looking for experienced management teams and generally requires a board seat. The firm looks to take company through significant value inflection points acting as a very hand on investor. The firm almost always leads or co-leads investment rounds.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Tags: , , , , ,

← Older Entries
Newer Entries →